Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 May 25;12(6):801.
doi: 10.3390/genes12060801.

Biomarkers in Different Asthma Phenotypes

Sanja Popović-Grle  1   2 , Anamarija Štajduhar  1 , Marina Lampalo  1 , Dina Rnjak  1
Affiliations
Review

Biomarkers in Different Asthma Phenotypes

Sanja Popović-Grle et al. Genes (Basel). .

Abstract

Asthma is the most common respiratory disease. It has multiple phenotypes thatcan be partially differentiated by measuring the disease's specific characteristics-biomarkers. The pathogenetic mechanisms are complex, and it is still a challenge to choose suitable biomarkers to adequately stratify patients, which became especially important with the introduction of biologicals in asthma treatment. Usage of biomarkers and an understanding of the underlying pathobiological mechanisms lead to the definition of endotypes. Asthma can be broadly divided into two endotypes, T2-high and T2-low. The right combination of various biomarkers in different phenotypes is under investigation, hoping to help researchers and clinicians in better disease evaluation since theindividual approach and personalized medicine are imperative. Multiple biomarkers are superior to a single biomarker.

Keywords: asthma phenotype; biomarkers; clusters; eosinophils.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. GBD 2015 Chronic Respiratory Disease Collaborators Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: A systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir. Med. 2017;5:691–706. doi: 10.1016/S2213-2600(17)30293-X. - DOI - PMC - PubMed
    1. Lambrecht B.N., Hammad H. The immunology of asthma. Nat. Immunol. 2015;16:45–56. doi: 10.1038/ni.3049. - DOI - PubMed
    1. Reddel H.K., Bateman E.D., Becker A., Boulet L.P., Cruz A.A., Drazen J.M., Haahtela T., Hurd S.S., Inoue H., De Jongste J.C., et al. A summary of the new GINA strategy: A roadmap to asthma control. Eur. Respir. J. 2015;46:622–639. doi: 10.1183/13993003.00853-2015. - DOI - PMC - PubMed
    1. Rackemann F.M. A working classification of asthma. Am. J. Med. 1947;3:601–606. doi: 10.1016/0002-9343(47)90204-0. - DOI - PubMed
    1. Fajt M.L., Wenzel S.E. Asthma phenotypes and the use of biologic medications in asthma and allergic disease: The next steps toward personalized care. J. Allergy Clin. Immunol. 2015;135:299–310. doi: 10.1016/j.jaci.2014.12.1871. - DOI - PubMed